Andrew E. Place

3.6k total citations
55 papers, 1.6k citations indexed

About

Andrew E. Place is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Oncology. According to data from OpenAlex, Andrew E. Place has authored 55 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Public Health, Environmental and Occupational Health, 19 papers in Hematology and 17 papers in Oncology. Recurrent topics in Andrew E. Place's work include Acute Lymphoblastic Leukemia research (33 papers), Childhood Cancer Survivors' Quality of Life (14 papers) and Acute Myeloid Leukemia Research (13 papers). Andrew E. Place is often cited by papers focused on Acute Lymphoblastic Leukemia research (33 papers), Childhood Cancer Survivors' Quality of Life (14 papers) and Acute Myeloid Leukemia Research (13 papers). Andrew E. Place collaborates with scholars based in United States, Canada and Australia. Andrew E. Place's co-authors include Kornélia Polyák, Sung Jin Huh, Gordon W. Gribble, Tadashi Honda, Michael B. Sporn, Nanjoo Suh, Yukiko Honda, Charlotte R. Williams, Renee Risingsong and Anupam Agarwal and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Andrew E. Place

51 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew E. Place United States	16	862	472	220	217	201	55	1.6k
Dapeng Wu China	24	903 1.0×	481 1.0×	421 1.9×	84 0.4×	252 1.3×	88	1.8k
Ken Ohmine Japan	21	605 0.7×	528 1.1×	124 0.6×	64 0.3×	368 1.8×	82	1.4k
Francesca Buontempo Italy	22	699 0.8×	192 0.4×	116 0.5×	257 1.2×	278 1.4×	34	1.2k
Teresa A. Smolarek United States	26	742 0.9×	599 1.3×	173 0.8×	96 0.4×	183 0.9×	68	2.2k
Min Du United States	16	770 0.9×	233 0.5×	222 1.0×	527 2.4×	610 3.0×	34	1.5k
Jaideep V. Thottassery United States	18	570 0.7×	565 1.2×	142 0.6×	107 0.5×	72 0.4×	31	1.2k
Lita A. Freeman United States	35	1.3k 1.6×	585 1.2×	439 2.0×	47 0.2×	114 0.6×	73	3.2k
Beata Smolarz Poland	23	1.2k 1.4×	697 1.5×	728 3.3×	114 0.5×	79 0.4×	150	2.4k
Tyler Lahusen United States	25	1.7k 2.0×	1.3k 2.7×	375 1.7×	73 0.3×	83 0.4×	35	3.2k
Jisong Cui United States	21	559 0.6×	751 1.6×	130 0.6×	64 0.3×	481 2.4×	27	2.2k

Countries citing papers authored by Andrew E. Place

Since Specialization

Citations

This map shows the geographic impact of Andrew E. Place's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew E. Place with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew E. Place more than expected).

Fields of papers citing papers by Andrew E. Place

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew E. Place. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew E. Place. The network helps show where Andrew E. Place may publish in the future.

Co-authorship network of co-authors of Andrew E. Place

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew E. Place. A scholar is included among the top collaborators of Andrew E. Place based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew E. Place. Andrew E. Place is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shulman, David S., Kieuhoa T. Vo, Frank M. Balis, et al.. (2025). A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors. Cancer Medicine. 14(23). e71417–e71417.

Valtis, Yannis K., Yael Flamand, Shai Shimony, et al.. (2024). Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia. 38(3). 482–490. 5 indexed citations

Shimony, Shai, Yael Flamand, Yannis K. Valtis, et al.. (2024). Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen. Blood Cancer Journal. 14(1). 191–191. 2 indexed citations

Tsai, Harrison, Mark F Sabbagh, Meagan Montesion, et al.. (2024). Acute Promyelocytic Leukemia With Torque Teno Mini Virus::RARA Fusion: An Approach to Screening and Diagnosis. Modern Pathology. 37(7). 100509–100509. 7 indexed citations

Place, Andrew E., et al.. (2023). Use of the osmolal gap in diagnosing mixed physiology hyponatremia in a child with B‐cell acute lymphoblastic leukemia. SHILAP Revista de lepidopterología. 11(6). e7428–e7428. 1 indexed citations

Stein, Emily M., Steven G. DuBois, Katie A. Greenzang, et al.. (2023). Establishing a Sociodemographic Data Banking Study in Patients with Hematologic Disorders - a Feasibility Assessment. Blood. 142(Supplement 1). 2384–2384. 1 indexed citations

Karol, Seth E., Stanley Pounds, Jeffery M. Klco, et al.. (2023). Preliminary Safety and Efficacy of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia: Selclax. Blood. 142(Supplement 1). 56–56. 1 indexed citations

Badawi, Mohamed, Rajeev Menon, Andrew E. Place, et al.. (2023). Venetoclax Penetrates the Blood Brain Barrier: A Pharmacokinetic Analysis in Pediatric Leukemia Patients. Journal of Cancer. 14(7). 1151–1156. 12 indexed citations

Valtis, Yannis K., Andrew E. Place, Lewis B. Silverman, et al.. (2022). Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. British Journal of Haematology. 198(3). 421–430. 1 indexed citations

10.

Place, Andrew E., Christine Duncan, Steven Margossian, et al.. (2021). Low Rates of Venoocclusive Disease and Non-Relapse Mortality in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation Following Inotuzumab Ozogamicin Reinduction for Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia. Blood. 138(Supplement 1). 2853–2853.

11.

Shulman, David S., Stacey L. Edwards, Catherine Clinton, et al.. (2021). Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. Cancer Medicine. 10(7). 2310–2318. 6 indexed citations

12.

Place, Andrew E., Yana Pikman, Kristen E. Stevenson, et al.. (2018). Phase I trial of the mTOR inhibitor everolimus in combination with multi‐agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatric Blood & Cancer. 65(7). e27062–e27062. 43 indexed citations

13.

Place, Andrew E., Kelly C. Goldsmith, Jean‐Pierre Bourquin, et al.. (2018). Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies. Future Oncology. 14(21). 2115–2129. 39 indexed citations

14.

Pikman, Yana, Gabriela Alexe, Giovanni Roti, et al.. (2016). Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research. 23(4). 1012–1024. 81 indexed citations

15.

Marusyk, Andriy, Doris P. Tabassum, Michalina Janiszewska, et al.. (2016). Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Research. 76(22). 6495–6506. 96 indexed citations

16.

Place, Andrew E., Sung Jin Huh, & Kornélia Polyák. (2011). The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Research. 13(6). 227–227. 312 indexed citations

17.

Liby, Karen T., Thomas Hock, Mark M. Yore, et al.. (2005). The Synthetic Triterpenoids, CDDO and CDDO-Imidazolide, Are Potent Inducers of Heme Oxygenase-1 and Nrf2/ARE Signaling. Cancer Research. 65(11). 4789–4798. 239 indexed citations

18.

Suh, Nanjoo, Anita B. Roberts, Stephanie Birkey Reffey, et al.. (2003). Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling.. PubMed. 63(6). 1371–6. 76 indexed citations

19.

Honda, Tadashi, Yukiko Honda, Frank G. Favaloro, et al.. (2002). A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorganic & Medicinal Chemistry Letters. 12(7). 1027–1030. 129 indexed citations

20.

Pandey, Pramod S., Shalom Avraham, Andrew E. Place, et al.. (1999). Bcl-xL Blocks Activation of Related Adhesion Focal Tyrosine Kinase/Proline-rich Tyrosine Kinase 2 and Stress-activated Protein Kinase/c-Jun N-terminal Protein Kinase in the Cellular Response to Methylmethane Sulfonate. Journal of Biological Chemistry. 274(13). 8618–8623. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact